The Medicines Company (NASDAQ: MDCO) has announced a nationwide recall for 11 lots of Cleviprex injectable emulsion due to the possibility of a presence of visible particulate matter which has been observed in various vials during a routine annual inspection. The company has not received any complaints or reports of adverse effects related to this issue. MDCO and the U.S. FDA are in cooperation involving the recall.
Free Hot Penny Stocks, an online financial publication, provides investors timely stock market alerts. Free hot penny stocks profiles stock picks that could generate higher returns than average. These penny stocks include stocks with news, chart breakouts or increased volume.
Sign Up Today for our Penny Stock Newsletter
The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of medicines to the worldwide hospital marketplace. The Company has two marketed products, Angiomax (bivalirudin) and Cleviprex (clevidipine butyrate) injectable emulsion, two products in late-stage development, cangrelor and oritavancin, which the Company acquired in February 2009, and one compound, CU-2010, scheduled to enter clinical development during 2009.
Sign Up for Free Hot Penny Stocks’ FREE Penny Stock Newsletter.
About Us
Free Hot Penny Stocks is a financial website and independent electronic publication that provides information and free penny stock alerts on selected publicly traded companies. We also track small cap companies and other stocks that may be positioned to break out. These penny stocks might have news, increased volume or chart breakouts. These penny stocks that are alerted could generate greater than average returns. Feel free to visit our penny stock forum to discuss other penny stock picks or penny stocks that you might own.
Free Hot Penny Stocks is not a registered investment advisor or broker-dealer. Please do your own Due Diligence before investing in any of the stocks mentioned above. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
